Modulators of dopamine neurotransmission

USRE46117E1 · kind E1 · reissue

Assignee

• TEVA PHARMACEUTICALS INTERNATIONAL GMBH · CH

Inventors

• Clas Sonesson · Lindome, SE
• Bengt R. Andersson · Göteborg, SE
• Susanna Waters · Handen, SE
• Nicholas Waters · Handen, SE
• Joakim Tedroff · Danderyd, SE

Key dates

• Filing date: Apr 22, 2015
• Grant date: Aug 23, 2016
• Expiry date: Apr 22, 2035

Classification

• Technology area (CPC —): General

Abstract

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed